Freiberger Verena, Amann Kerstin, Heemann Uwe, Frank Helga
Department of Nephrology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Germany.
Transpl Int. 2009 Nov;22(11):1110-3. doi: 10.1111/j.1432-2277.2009.00897.x. Epub 2009 May 20.
Recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation with nephrotic syndrome is a serious problem with a high risk of graft loss. The therapeutic role of renin-angiotensin-system (RAS) blockers in recurrent FSGS is not clear. We present the safety and efficacy of an intensified triple RAS blockade with an ACE-inhibitor, an AT 1 receptor blocker and the direct renin inhibitor aliskiren in a 29-year-old renal transplant recipient with biopsy proven recurrence of FSGS and relapsing severe nephrotic syndrome. We subsequently used full dose ramipril, candesartan and aliskiren under a close monitoring of kidney function and electrolytes and examined the effect on proteinuria, clinical course and tolerability over 12 months. We found a significant and sustained antiproteinuric effect under triple RAS blockade. RAS blockade was generally well tolerated. This can offer a new therapeutic approach in selected hypertensive patients with recurrent FSGS.
肾移植后复发性局灶节段性肾小球硬化(FSGS)伴肾病综合征是一个严重问题,移植肾丢失风险高。肾素-血管紧张素系统(RAS)阻滞剂在复发性FSGS中的治疗作用尚不清楚。我们报告了一名29岁肾移植受者强化三联RAS阻断治疗的安全性和有效性,该受者经活检证实为FSGS复发且肾病综合征复发严重,使用了一种血管紧张素转换酶抑制剂、一种AT1受体阻滞剂和直接肾素抑制剂阿利吉仑进行强化三联RAS阻断。随后,我们在密切监测肾功能和电解质的情况下使用了全剂量雷米普利、坎地沙坦和阿利吉仑,并在12个月内检查了对蛋白尿、临床病程和耐受性的影响。我们发现三联RAS阻断下有显著且持续的抗蛋白尿作用。RAS阻断总体耐受性良好。这可为选定的复发性FSGS高血压患者提供一种新的治疗方法。